Xenon Pauses New Enrollment in Depression Drug Trials After Side Effects

Xenon Pharmaceuticals voluntarily paused new patient enrollment in its Phase 3 trials of azetukalner for major depressive disorder and bipolar depression on September 18, 2026. The company said an internal analysis had turned up neuropsychiatric side effects that had not appeared in earlier testing of the drug, according to BioPharma Dive.

The stock reflected the news immediately, falling as much as 30 percent in early trading before closing down 26.8 percent, according to RTTNews, a drop that erased the gains the stock had built on earlier positive epilepsy trial data.

What the pause covers, and what it does not

The pause applies to two psychiatric programs: X-NOVA, three double-blind trials testing a 20-milligram dose of azetukalner in roughly 450 patients each for major depressive disorder, and X-CEED, two similarly designed trials in roughly 400 patients each for bipolar depression, according to RTTNews. One trial, X-NOVA2, had already reached about 360 of its 450-patient target, roughly 80 percent enrolled, when Xenon stopped adding new patients. Patients already enrolled across every trial are continuing treatment; only new enrollment has stopped, and topline data from X-NOVA2 are still expected in early 2027.

The side effects were not seen in the company's earlier Phase 2 X-NOVA study, according to BioPharma Dive, and Xenon has described them as mild to moderate, short in duration, and reversible. The company has not released a public count of how many patients were affected or a breakdown of specific symptoms. Chris Kenney, Xenon's chief medical officer, said the events were consistent with the drug's known mechanism and pointed to the epilepsy program's safety record for reassurance.

“We remain very confident in the product profile of azetukalner.”

The epilepsy program keeps moving

The pause does not touch azetukalner's epilepsy program, which sits on a separate track. Xenon has filed a new drug application with the FDA for azetukalner as a focal-seizure treatment, based on the Phase 2b X-TOLE and Phase 3 X-TOLE2 trials, in which the company reports that all four tested doses reduced monthly seizure frequency compared with placebo. That program has accumulated more than 1,500 patient-years of safety data, according to RTTNews.

Gurufocus noted that Xenon has no approved commercial products generating revenue yet, part of why a single trial disclosure moved the stock by more than a quarter of its value in one session. That reaction reads as larger than the company's own description of mild, reversible side effects would suggest, and Xenon has not published the case-level detail investors would need to judge that gap for themselves. How this move compares with other clinical-hold stock reactions across biotech is not established in the sources reviewed here.